Home ETF List About

Portfolio Holdings Detail for ISIN IE00BL3J3G74
Stock Name / FundiShares Core S&P 500 UCITS ETF MXN Hedged (Acc)
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity Type
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCSPXx(MXN) CXE

Holdings detail for INCY

Stock NameIncyte Corporation
TickerINCY(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS45337C1027
LEI549300Z4WN6JVZ3T4680

Show aggregate INCY holdings

News associated with INCY

Incyte Reaches Analyst Target Price
In recent trading, shares of Incyte Corporation (Symbol: INCY) have crossed above the average analyst 12-month target price of $84.18, changing hands for $84.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v - 2025-09-18 08:17:02
Incyte Reports Encouraging 24-Week Results From Phase 3 STOP-HS Program Of Povorcitinib
(RTTNews) - Incyte Corporation (INCY) on Wednesday announced encouraging 24-week data from the pivotal Phase 3 STOP-HS program evaluating povorcitinib in adults with hidradenitis suppurativa (HS). - 2025-09-17 03:26:09
Incyte Corporation (NASDAQ:INCY) Short Interest Update
Incyte Corporation (NASDAQ:INCY – Get Free Report) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totaling 9,600,000 shares, an increase of 29.4% from the July 31st total of 7,420,000 shares. Based on an average trading volume of 1,860,000 shares, the […] - 2025-09-11 04:51:36
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of “Hold” from Analysts
Incyte Corporation (NASDAQ:INCY – Get Free Report) has been assigned a consensus recommendation of “Hold” from the eighteen analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating on the company. The […] - 2025-08-26 02:32:54
Incyte (NASDAQ:INCY) Given New $73.00 Price Target at JPMorgan Chase & Co.
Incyte (NASDAQ:INCY – Free Report) had its price objective increased by JPMorgan Chase & Co. from $67.00 to $73.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. A number of other research firms also recently commented on INCY. Citigroup upped their price objective on […] - 2025-08-25 03:08:46
LABU, INCY, UTHR, REGN: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Charles Schwab Investment Management Inc. Purchases 38,962 Shares of Incyte Corporation (NASDAQ:INCY)
Charles Schwab Investment Management Inc. raised its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 2.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,682,029 shares of the biopharmaceutical company’s stock after purchasing an additional 38,962 […] - 2025-08-13 05:43:01
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Citigroup Raises Incyte (NASDAQ:INCY) Price Target to $103.00
Incyte (NASDAQ:INCY – Get Free Report) had its price objective lifted by equities researchers at Citigroup from $88.00 to $103.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s target price suggests a potential upside of 37.54% from the […] - 2025-08-01 04:32:55
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of “Hold” from Analysts
Shares of Incyte Corporation (NASDAQ:INCY – Get Free Report) have earned a consensus rating of “Hold” from the eighteen research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, twelve have given a hold recommendation and five have assigned a buy recommendation to the […] - 2025-08-01 03:04:43
Incyte Reaches Analyst Target Price
In recent trading, shares of Incyte Corporation (Symbol: INCY) have crossed above the average analyst 12-month target price of $76.09, changing hands for $77.38/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v - 2025-07-30 10:12:59
Mutual of America Capital Management LLC Sells 478 Shares of Incyte Corporation (NASDAQ:INCY)
Mutual of America Capital Management LLC lessened its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 2.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,719 shares of the biopharmaceutical company’s stock after selling 478 shares during the quarter. […] - 2025-07-22 08:02:58
Incyte Corporation (NASDAQ:INCY) Shares Sold by Ballentine Partners LLC
Ballentine Partners LLC trimmed its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 12.2% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 4,686 shares of the biopharmaceutical company’s stock after selling 649 shares during the quarter. Ballentine Partners LLC’s holdings in Incyte were worth $284,000 at the end of the most recent […] - 2025-07-17 05:12:56
Cerity Partners LLC Has $8.04 Million Stock Position in Incyte Corporation (NASDAQ:INCY)
Cerity Partners LLC lifted its holdings in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 103.5% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 132,703 shares of the biopharmaceutical company’s stock after buying an additional 67,495 shares during the period. Cerity Partners LLC owned […] - 2025-07-16 05:40:51
Incyte (NASDAQ:INCY) Price Target Cut to $67.00 by Analysts at JPMorgan Chase & Co.
Incyte (NASDAQ:INCY – Get Free Report) had its price objective decreased by equities research analysts at JPMorgan Chase & Co. from $68.00 to $67.00 in a report released on Monday,Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential downside of […] - 2025-07-16 04:26:52
Sheila A. Denton Sells 599 Shares of Incyte Corporation (NASDAQ:INCY) Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Sheila A. Denton sold 599 shares of the company’s stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $68.61, for a total value of $41,097.39. Following the completion of the sale, the executive vice president owned 26,504 […] - 2025-07-09 06:12:52
Incyte Corporation (NASDAQ:INCY) EVP Barry P. Flannelly Sells 10,903 Shares of Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Barry P. Flannelly sold 10,903 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $68.15, for a total transaction of $743,039.45. Following the sale, the executive vice president directly owned 39,744 shares of the […] - 2025-07-08 06:54:44
Incyte Corporation (NASDAQ:INCY) EVP Sells $587,248.55 in Stock
Incyte Corporation (NASDAQ:INCY – Get Free Report) EVP Vijay K. Iyengar sold 8,617 shares of the company’s stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $68.15, for a total transaction of $587,248.55. Following the completion of the sale, the executive vice president directly owned 37,701 shares […] - 2025-07-08 06:20:54
Incyte Corporation (NASDAQ:INCY) Shares Sold by Vontobel Holding Ltd.
Vontobel Holding Ltd. trimmed its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 16.8% in the first quarter, Holdings Channel.com reports. The institutional investor owned 7,875 shares of the biopharmaceutical company’s stock after selling 1,592 shares during the quarter. Vontobel Holding Ltd.’s holdings in Incyte were worth $477,000 as of its most recent filing […] - 2025-07-08 04:46:50
Sumitomo Mitsui Trust Group Inc. Purchases 25,844 Shares of Incyte Corporation (NASDAQ:INCY)
Sumitomo Mitsui Trust Group Inc. increased its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 5.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 473,186 shares of the biopharmaceutical company’s stock after purchasing an additional 25,844 shares […] - 2025-07-03 05:25:07
Incyte Corporation (NASDAQ:INCY) Shares Purchased by Chevy Chase Trust Holdings LLC
Chevy Chase Trust Holdings LLC raised its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 0.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,241 shares of the biopharmaceutical company’s stock after purchasing an additional 334 shares during the quarter. […] - 2025-06-27 05:36:52
Janney Montgomery Scott LLC Boosts Stock Position in Incyte Corporation (NASDAQ:INCY)
Janney Montgomery Scott LLC grew its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 10.2% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 29,793 shares of the biopharmaceutical company’s stock after purchasing an additional 2,746 shares during the period. Janney Montgomery Scott LLC’s holdings in Incyte were worth $1,804,000 as of its […] - 2025-06-27 04:26:49
State of Alaska Department of Revenue Purchases 590 Shares of Incyte Corporation (NASDAQ:INCY)
State of Alaska Department of Revenue lifted its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 3.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,824 shares of the biopharmaceutical company’s stock after acquiring an additional 590 shares […] - 2025-06-26 05:56:50
Kentucky Retirement Systems Insurance Trust Fund Makes New Investment in Incyte Corporation (NASDAQ:INCY)
Kentucky Retirement Systems Insurance Trust Fund bought a new stake in Incyte Corporation (NASDAQ:INCY – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,624 shares of the biopharmaceutical company’s stock, valued at approximately $280,000. A number […] - 2025-06-26 05:03:09
Incyte Corporation (NASDAQ:INCY) Shares Acquired by Wealth Enhancement Advisory Services LLC
Wealth Enhancement Advisory Services LLC lifted its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 66.5% during the 1st quarter, HoldingsChannel.com reports. The fund owned 79,735 shares of the biopharmaceutical company’s stock after acquiring an additional 31,851 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Incyte were worth $4,828,000 […] - 2025-06-26 04:30:52
Assenagon Asset Management S.A. Has $536,000 Stock Position in Incyte Corporation (NASDAQ:INCY)
Assenagon Asset Management S.A. raised its position in Incyte Corporation (NASDAQ:INCY – Free Report) by 37.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,846 shares of the biopharmaceutical company’s stock after acquiring an additional 2,418 shares during the period. […] - 2025-06-20 04:54:50
Incyte Corporation (NASDAQ:INCY) Shares Sold by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC lowered its position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 41.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,117 shares of the biopharmaceutical company’s stock after selling 12,867 shares during the period. Exchange Traded Concepts […] - 2025-06-19 05:43:03
Fifth Third Bancorp Has $551,000 Holdings in Incyte Corporation (NASDAQ:INCY)
Fifth Third Bancorp raised its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 2.0% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 9,103 shares of the biopharmaceutical company’s stock after acquiring an additional 179 shares during the quarter. Fifth Third Bancorp’s holdings in Incyte were worth $551,000 at the end of […] - 2025-06-18 04:56:49
Incyte (NASDAQ:INCY) Raised to “Buy” at Stifel Nicolaus
Incyte (NASDAQ:INCY – Get Free Report) was upgraded by equities researchers at Stifel Nicolaus from a “hold” rating to a “buy” rating in a research report issued on Monday, MarketBeat reports. The brokerage currently has a $107.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $75.00. Stifel Nicolaus’ price […] - 2025-06-18 02:22:54
Stocks Settle Higher on Possible De-Escalation of Israel-Iran War
The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.94%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.42%. June E-mini S&P futures (ESM25 ) are up +1.00%, and June E-mini Nasdaq futures... - 2025-06-17 13:23:43

iShares Core S&P 500 UCITS ETF MXN Hedged (Acc) INCY holdings

DateNumber of INCY Shares HeldBase Market Value of INCY SharesLocal Market Value of INCY SharesChange in INCY Shares HeldChange in INCY Base ValueCurrent Price per INCY Share HeldPrevious Price per INCY Share Held
2025-09-25 (Thursday)376,525INCY holding increased by 308USD 30,747,032INCY holding decreased by -915391USD 30,747,032308USD -915,391 USD 81.66 USD 84.16
2025-09-24 (Wednesday)376,217USD 31,662,423USD 31,662,423
2025-09-18 (Thursday)375,073INCY holding increased by 22USD 32,256,278INCY holding increased by 451953USD 32,256,27822USD 451,953 USD 86 USD 84.8
2025-09-17 (Wednesday)375,051INCY holding increased by 198USD 31,804,325INCY holding increased by 354158USD 31,804,325198USD 354,158 USD 84.8 USD 83.9
2025-09-16 (Tuesday)374,853USD 31,450,167USD 31,450,167
2025-09-15 (Monday)374,765USD 31,157,962USD 31,157,962
2025-09-12 (Friday)374,545USD 31,124,690USD 31,124,690
2025-09-11 (Thursday)374,479INCY holding increased by 110USD 32,268,855INCY holding decreased by -20471USD 32,268,855110USD -20,471 USD 86.17 USD 86.25
2025-09-10 (Wednesday)374,369USD 32,289,326INCY holding increased by 243340USD 32,289,3260USD 243,340 USD 86.25 USD 85.6
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of INCY by Blackrock for IE00BL3J3G74

Show aggregate share trades of INCY

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-25BUY308 81.660* 68.38
2025-09-18BUY22 86.000* 68.28
2025-09-17BUY198 84.800* 68.18
2025-09-11BUY110 86.170* 68.07
2025-09-09BUY110 85.600* 67.85
2025-07-24BUY22 70.490* 67.83
2025-07-23BUY132 70.690* 67.81
2025-07-22BUY198 68.900* 67.81
2025-07-21BUY44 67.380* 67.81
2025-07-18SELL-220 67.860* 67.81 Profit of 14,918 on sale
2025-07-17BUY22 68.940* 67.80
2025-07-16BUY88 69.230* 67.79
2025-07-15SELL-330 68.250* 67.79 Profit of 22,371 on sale
2025-07-14BUY176 69.980* 67.78
2025-07-11SELL-44 68.590* 67.77 Profit of 2,982 on sale
2025-07-10BUY176 70.340* 67.75
2025-07-09BUY176 68.720* 67.75
2025-07-08BUY132 67.670* 67.75
2025-07-07SELL-506 67.270* 67.75 Profit of 34,282 on sale
2025-07-02SELL-638 68.170* 67.74 Profit of 43,217 on sale
2025-06-30BUY374 68.100* 67.74
2025-06-27BUY198 68.370* 67.73
2025-06-25SELL-44 67.550* 67.71 Profit of 2,979 on sale
2025-06-24BUY22 69.010* 67.70
2025-06-23BUY572 67.260* 67.71
2025-06-18SELL-132 68.270* 67.70 Profit of 8,936 on sale
2025-06-13SELL-66 67.750* 67.66 Profit of 4,466 on sale
2025-06-12BUY66 69.220* 67.65
2025-06-11BUY88 68.850* 67.64
2025-06-06SELL-110 68.770* 67.60 Profit of 7,436 on sale
2025-06-05SELL-66 67.240* 67.60 Profit of 4,462 on sale
2025-06-04SELL-88 67.420* 67.60 Profit of 5,949 on sale
2025-06-02BUY286 65.310* 67.62
2025-05-30SELL-63 65.060* 67.64 Profit of 4,262 on sale
2025-05-29BUY22 66.040* 67.66
2025-05-28SELL-22 64.930* 67.68 Profit of 1,489 on sale
2025-05-27BUY242 65.350* 67.70
2025-05-23SELL-440 64.245* 67.76 Profit of 29,812 on sale
2025-05-22SELL-484 64.510* 67.78 Profit of 32,807 on sale
2025-05-21BUY22 64.780* 67.81
2025-05-20BUY176 65.300* 67.83
2025-05-19BUY638 63.810* 67.86
2025-05-16BUY594 63.310* 67.90
2025-05-15BUY484 62.760* 67.95
2025-05-14BUY440 61.160* 68.01
2025-05-13SELL-88 60.810* 68.07 Profit of 5,990 on sale
2025-05-12BUY22 60.850* 68.14
2025-05-09BUY66 58.980* 68.22
2025-05-08SELL-638 59.730* 68.30 Profit of 43,575 on sale
2025-05-07SELL-308 59.550* 68.38 Profit of 21,061 on sale
2025-05-06BUY770 59.610* 68.46
2025-05-02BUY66 62.530* 68.58
2025-05-01SELL-110 62.030* 68.64 Profit of 7,551 on sale
2025-04-30BUY66 62.660* 68.70
2025-04-29BUY154 60.430* 68.78
2025-04-28BUY328 59.520* 68.87
2025-04-25BUY308 59.160* 68.97
2025-04-24BUY88 58.970* 69.07
2025-04-23BUY242 58.000* 69.18
2025-04-22SELL-134 57.380* 69.31 Profit of 9,287 on sale
2025-04-17BUY44 58.210* 69.54
2025-04-16BUY88 57.730* 69.67
2025-04-15BUY440 58.460* 69.79
2025-04-11BUY550 56.870* 70.04
2025-04-10BUY902 55.170* 70.21
2025-04-09BUY176 58.860* 70.34
2025-04-08BUY462 56.970* 70.49
2025-04-07BUY527 60.290* 70.61
2025-04-04SELL-1,320 60.580* 70.72 Profit of 93,354 on sale
2025-04-02BUY154 62.330* 70.82
2025-03-31SELL-594 60.550* 71.06 Profit of 42,212 on sale
2025-03-28SELL-374 60.600* 71.19 Profit of 26,626 on sale
2025-03-27SELL-110 60.680* 71.32 Profit of 7,845 on sale
2025-03-26BUY198 61.260* 71.45
2025-03-25SELL-264 62.080* 71.57 Profit of 18,894 on sale
2025-03-24BUY154 62.780* 71.68
2025-03-21BUY264 61.920* 71.81
2025-03-19BUY42 60.340* 72.11
2025-03-18SELL-396 60.000* 72.27 Profit of 28,620 on sale
2025-03-17BUY418 62.010* 72.41
2025-03-14BUY374 67.860* 72.48
2025-03-13BUY1,846 67.710* 72.54
2025-03-12BUY880 67.730* 72.61
2025-03-11BUY352 68.070* 72.68
2025-03-07BUY208 70.790* 72.73
2025-03-06SELL-198 70.090* 72.77 Profit of 14,408 on sale
2025-03-05BUY684 69.810* 72.81
2025-03-04BUY132 69.680* 72.86
2025-03-03BUY594 70.260* 72.90
2025-02-28SELL-154 73.500* 72.89 Profit of 11,226 on sale
2025-02-27BUY22 73.180* 72.89
2025-02-26SELL-44 74.300* 72.87 Profit of 3,206 on sale
2025-02-25BUY418 74.400* 72.84
2025-02-21BUY308 72.110* 72.83
2025-02-20BUY176 71.380* 72.86
2025-02-19BUY44 70.160* 72.91
2025-02-18BUY110 71.270* 72.94
2025-02-13BUY374 70.010* 73.09
2025-02-12BUY132 69.050* 73.18
2025-02-11SELL-44 66.330* 73.32 Profit of 3,226 on sale
2025-02-07SELL-176 74.130* 73.40 Profit of 12,919 on sale
2025-02-06BUY88 74.950* 73.37
2025-02-04BUY770 74.120* 73.31
2025-02-03BUY286 73.740* 73.30
2025-01-31BUY66 74.160* 73.28
2025-01-30BUY44 73.770* 73.27
2025-01-29BUY418 73.720* 73.26
2025-01-28BUY198 73.150* 73.26
2025-01-27BUY308 72.640* 73.28
2025-01-24BUY198 72.590* 73.30
2025-01-23BUY572 72.530* 73.32
2025-01-02BUY726 69.530* 73.42
2024-12-30BUY5,711 68.420* 73.57
2024-12-10BUY154 72.480* 73.60
2024-12-09BUY176 72.110* 73.65
2024-12-06BUY264 75.920* 73.58
2024-12-05BUY66 74.920* 73.53
2024-12-04BUY242 74.620* 73.50
2024-12-03BUY776 72.030* 73.55
2024-12-02BUY65 73.240* 73.56
2024-11-29BUY506 74.590* 73.52
2024-11-27BUY594 75.450* 73.36
2024-11-26BUY1,276 74.800* 73.30
2024-11-25BUY1,320 73.520* 73.29
2024-11-22BUY1,540 71.720* 73.36
2024-11-21BUY242 70.390* 73.51
2024-11-20BUY220 71.050* 73.64
2024-11-19BUY198 70.560* 73.81
2024-11-18BUY1,782 76.970* 73.62
2024-11-12BUY616 80.580* 73.19
2024-11-11BUY418 81.530* 72.63
2024-11-08BUY316 83.380* 71.87
2024-11-07BUY1,958 82.340* 71.06
2024-11-06BUY594 80.950* 70.24
2024-11-05BUY876 77.280* 69.60
2024-11-04BUY154 75.750* 68.98
2024-11-01BUY352 76.130* 68.19
2024-10-31BUY88 74.120* 67.44
2024-10-30BUY219 73.930* 66.52
2024-10-29BUY638 73.600* 65.34
2024-10-28SELL-154 65.690* 65.27 Profit of 10,051 on sale
2024-10-25BUY264 65.070* 65.32
2024-10-24BUY176 65.240* 65.34
2024-10-23BUY220 65.170* 65.43
2024-10-22BUY1,185 65.590* 65.27
2024-10-21BUY616 65.270* 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of INCY

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19321,923395451,11071.4%
2025-09-18244,9471,423469,74752.1%
2025-09-17277,858779546,95350.8%
2025-09-16359,781946576,37962.4%
2025-09-15347,4534582,22859.7%
2025-09-12353,0400631,53455.9%
2025-09-11448,7333,894739,70160.7%
2025-09-10490,727248671,93273.0%
2025-09-09515,3951,822682,79175.5%
2025-09-08308,184119479,82864.2%
2025-09-05256,7192,505512,04950.1%
2025-09-04422,6241,507834,71750.6%
2025-09-03381,6797,777624,92261.1%
2025-09-02547,12015,396816,26767.0%
2025-08-29148,294262304,42748.7%
2025-08-28164,0080347,48047.2%
2025-08-27248,926453513,40148.5%
2025-08-26365,1306709,32051.5%
2025-08-25478,1301,306642,31974.4%
2025-08-22344,3522,023596,30157.7%
2025-08-21198,7294,881335,30159.3%
2025-08-20351,6993,977555,34563.3%
2025-08-19343,1103,146574,32859.7%
2025-08-18366,1244,996653,10356.1%
2025-08-15480,8858,035625,79776.8%
2025-08-14593,55436,654806,06873.6%
2025-08-13845,18198,1601,257,50367.2%
2025-08-12462,89642,208678,68968.2%
2025-08-11385,211696595,89264.6%
2025-08-08248,925738426,18758.4%
2025-08-07268,864929420,48663.9%
2025-08-06554,642891731,48475.8%
2025-08-05361,6872,092623,87958.0%
2025-08-04338,0051,464519,15065.1%
2025-08-01414,814828572,87972.4%
2025-07-31570,8456,148777,41773.4%
2025-07-30471,30314,166881,19453.5%
2025-07-29966,64010,5811,593,70160.7%
2025-07-28382,23662625,51061.1%
2025-07-25216,96749422,99051.3%
2025-07-24348,27623528,51765.9%
2025-07-23297,903583487,29761.1%
2025-07-22267,987172446,48960.0%
2025-07-21223,626380406,72955.0%
2025-07-18241,218108471,58951.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.